Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for AD and dementia with Lewy bodies (DLB) (1, 5, 6), whereas APOE2, a well-established longevity determinant, affords protection against the disease (7, 8).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [1]
In the citing paper
“Familial Alzheimer’s disease, which has an autosomal dominant form of inheritance and early onset, has been associated with mutations in APP, PSEN1 and PSEN2, three genes that are critical for beta amyloid (Aβ) production61.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [61]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Despite the lack of MAPT mutations in AD, it is likely that tau dysfunction still contributes to AD ris”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“, none of these candidates has been proved to consistently influence disease risk or onset age in more than a handful of sample”
BackgroundSelf-citation
Research works printed but not linked: 1
- Meyer, J. M. & Breitner, J. C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 81, 92–97 (1998). · DOI · Paper page
Cited by
Items 301–400 of 754
A microfiber scaffold-based 3D in vitro human neuronal culture model of Alzheimer's disease
Ranjan, V., Qiu, L., Lee, J. W. L., Chen, X., Jang, S. E., Chai, C., Lim, K., Tan, E., Zhang, Y., Huang, W., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00833h · Cited by 38
Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03415-w · Cited by 35
Lane, R. F., Shineman, D. W., Steele, J., Lee, L. H., & Fillit, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00007-6 · Cited by 38
Does the term ‘trophic’ actually mean anti-amyloidogenic? The case of NGF
Calissano, P., Amadoro, G., Matrone, C., Ciafrè, S., Marolda, R., Corsetti, V., Ciotti, M. T., Mercanti, D., Luzio, A. D., Severini, C., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.38 · Cited by 39
Bermejo‐Pareja, F., & del Ser, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020536 · Cited by 42
Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors
Liu, L., Aboud, O., Jones, R. A., Mrak, R. E., Griffin, W. S. T., & Barger, S. W. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-175 · Cited by 33
Raven, F., Ward, J. F., Zoltowska, K. M., Wan, Y., Bylykbashi, E., Miller, S., Shen, X., Choi, S. H., Rynearson, K. D., Berezovska, O., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.08.028 · Cited by 37
“Biochemical studies of these mutations show a common endpoint which is primarily characterized by increases in the levels of Aβ42 and the Aβ (42:40) ratios, driving the aggregation of Aβ into neurotoxic oligomeric assemblies (Bertram and Tanzi, 2008; Tanzi and Bertram, 2005).”
BackgroundSelf-citationModelling Alzheimer's disease: Insights fromin vivotoin vitrothree-dimensional culture platforms
Ranjan, V., Qiu, L., Tan, E., Zeng, L., & Zhang, Y. (2018) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2728 · Cited by 46
Genetic Analyses of Alzheimer’s Disease in China: Achievements and Perspectives
Zhang, D., Xu, M., Bi, R., & Yao, Y. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00435 · Cited by 33
Kim, J.-M., Kim, S.-Y., Bae, K.-Y., Kim, S.-W., Shin, I.-S., Yang, S.-J., Song, Y.-H., & Yoon, J.-S. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.2.135 · Cited by 32
“Vascular risk score, median (IQR) score 01 (0-2) 01 (0-2) 1 (1-2) Z=0.”
GSK-3/CREB pathway involved in the gx-50's effect on Alzheimer's disease
Tang, M., Shi, S., Guo, Y., Xu, W., Wang, L., Chen, Y., Wang, Z., & Qiao, Z. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.008 · Cited by 32
Acetylcholinesterase inhibitor from Anthocleista vogelii leaf extracts
Ajayi, O. S., Aderogba, M. A., Obuotor, E. M., & Majinda, R. R. T. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.11.009 · Cited by 32
Wan, Y., Liang, Y., Liang, F., Shen, N., Shinozuka, K., Yu, J., Ran, C., Quan, Q., Tanzi, R. E., & Zhang, C. M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190562 · Cited by 32
Self-citationMolecular imaging of Alzheimer’s disease–related gamma-secretase in mice and nonhuman primates
Xu, Y., Wang, C., Wey, H., Liang, Y., Chen, Z., Choi, S. H., Ran, C., Rynearson, K. D., Bernales, D. R., Koegel, R. E., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20182266 · Cited by 32
“Although the underlying mechanisms of AD have not been completely elucidated, considerable evidence supports the “Aβ hypothesis,” positing that excessive accumulation of Aβ is the primary pathological event of AD, which induces the formation of NFTs, followed by neuroinflammation and neurodegeneration in AD (Bertram a…”
BackgroundSelf-citationCOVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences
Baazaoui, N., & Iqbal, K. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220105 · Cited by 37
Increased AβPP Processing in Familial Danish Dementia Patients
Matsuda, S., Tamayev, R., & D'Adamio, L. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110785 · Cited by 32
“The evidence that mutations in AβPP and in genes that regulate A PP processing, such as presenilins and BRI2, cause dementias [2, 6, 11, 13–16], emphasizes the relevance of A PP processing to AD pathogenesis.”
Wang, L.-Z., Yu, J.-T., Miao, D., Wu, Z.-C., Zong, Y., Wen, C.-Q., & Tan, L. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.007 · Cited by 32
The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases
Peng, J., & Zeng, X. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt73 · Cited by 36
“One dominant hypothesis concerning the etiology and pathogenesis of AD is the so-called amyloid cascade hypothesis [ 22 ].”
BackgroundInfluentialFeng, C., Yin, J., Yang, J., & Cao, L. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.12.017 · Cited by 31
“The majority of AD cases that occurred sporadically in later life is referred as late-onset AD (LOAD) (Bertram and Tanzi, 2008).”
InfluentialMulti-Modality Disease Modeling via Collective Deep Matrix Factorization
Wang, Q., Sun, M., Zhan, L., Thompson, P. M., Ji, S., & Zhou, J. (2017) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/3097983.3098164 · Cited by 36
Villa, C., Rivellini, E., Lavitrano, M., & Combi, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010029 · Cited by 35
“Among its three alleles (ε2, ε3 and ε4), individuals carrying the APOE ε4 allele are associated with increased risk and accelerated onset of AD by enhancing Aβ deposition into plaques and reducing its clearance from the brain [59].”
BackgroundWang, L., Pan, X., Wang, Y., Tang, H., Deng, Y., Ren, R., Xu, W. L., Ma, J., Wang, G., & Chen, S. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.10.015 · Cited by 33
“To date, mutations in three genes, Amyloid precursor (APP), Presenilin1 (PSEN1), Presenilin2 (PSEN2) have been identified to be associated with the rare, early-onset, autosomal dominant form of AD [2].”
BackgroundMandel, S. A., Morelli, M., Halperin, I. J. Y., & Korczyn, A. D. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0036-z · Cited by 39
“Detection of the mutations in these genes can identify at-risk family members, but it is not generalisable to sporadic AD [21, 22].”
BackgroundPS Dependent APP Cleavage Regulates Glucosylceramide Synthase and is Affected in Alzheimer's Disease
Grimm, M. O. W., Hundsdörfer, B., Grösgen, S., Mett, J., Zimmer, V. C., Stahlmann, C. P., Haupenthal, V. J., Rothhaar, T. L., Lehmann, J., Pätzold, A. J., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000362987 · Cited by 34
Magini, A., Polchi, A., Tozzi, A., Tancini, B., Tantucci, M., Urbanelli, L., Borsello, T., Calabresi, P., & Emiliani, C. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.11.001 · Cited by 31
Presenilins and the γ-secretase: still a complex problem
Small, D. H., Klaver, D. W., & Foa, L. C. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-7 · Cited by 37
“Then, in 1995, FAD mutations in two presenilin (PS) genes located on chromosome 14 (presenilin-1, PS1) and chromosome 1 (presenilin-2, PS2) were reported [15-17].”
BackgroundInfluentialWang, Z., Qin, W., Wei, C., Tang, Y., Zhao, L., Jin, H. M., Li, Y., Wang, Q., Luan, X., He, J., et al. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4881 · Cited by 37
“wileyonlinelibr complex.(1) The single greatest risk factor in sporadic AD is the genetic polymorphism in ApoE gene,(2,3) and about half of sporadic AD could be attributed to the single nucleotide polymorphisms (SNPs) of ApoE.”
BackgroundMancini, G., Dias, C., Lourenço, C. F., Laranjinha, J. A. N., Bem, A. F. D., & Ledo, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210122 · Cited by 34
“Furthermore, the (cid:2) 4 allele of apolipoprotein E ( APOE ) has consistently been demonstrated to be a genetic risk factor for sporadic AD, supporting a role for cholesterol in the pathogenesis of AD [7–9].”
Wang, X., Li, H., Sheng, Y., He, B., Liu, Z., Li, W., Yu, S., Wang, J., Zhang, Y., Chen, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116071 · Cited by 29
The SIRT2 Polymorphism rs10410544 and Risk of Alzheimer’s Disease: A Meta-analysis
Wei, W., Xu, X., Li, H., Zhang, Y., Han, D., Wang, Y., Yan, W., Wang, X., Zhang, J., Liu, N., et al. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8291-0 · Cited by 30
“Additionally, the APOE e4 allele is a well-established risk factor that has been shown to contribute to 40–50 % of the risk as a single factor (Bertram and Tanzi 2008; Crean et al. 2011).”
Sloan, C., Shen, L., West, J. D., Wishart, H. A., Flashman, L. A., Rabin, L. A., Santulli, R. B., Guerin, S. J., Rhodes, C. H., Tsongalis, G. J., et al. (2010) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31078 · Cited by 28
Liang, Y., Raven, F., Ward, J. F., Zhen, S. Y., Zhang, S., Sun, H., Miller, S., Choi, S. H., Tanzi, R. E., & Zhang, C. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200128 · Cited by 32
“The early-onset familial AD (FAD) cases (<60 years old; ∼ 5% cases) are usually associated with mutations in the amyloid precursor protein ( APP ), presenilin 1 ( PSEN1 ), and presenilin 2 ( PSEN2 ) [2–4].”
Self-citationIn Vitro and In Vivo Neuroprotective Effects of Sarcosine
Tanas, A., Tozlu, Ö. Ö., Gezmiş, T., Hacımüftüoğlu, A., El‐Aty, A. M. A., Ceylan, O., Mardinoğlu, A., & Türkez, H. (2022) · BioMed Research International · doi:10.1155/2022/5467498 · Cited by 31
Proteomic analysis of mitochondrial dysfunction in neurodegenerative diseases
Rodolfo, C., Ciccosanti, F., Giacomo, G. D., Piacentini, M., & Fimia, G. M. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.43 · Cited by 31
Wang, H.-F., Yu, J., Zhang, W., Wang, W., Liu, Q., Ma, X., Ding, H., & Tan, L. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.067 · Cited by 29
MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis
Das, S. K., Sarkar, D., Emdad, L., & Fisher, P. B. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.011 · Cited by 30
Association of a Functional NOS1 Promoter Repeat with Alzheimer's Disease in the VITA Cohort
Reif, A., Grünblatt, E., Herterich, S., Wichart, I., Rainer, M. K., Jungwirth, S., Danielczyk, W., Deckert, J., Tragl, K., Riederer, P. F., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101491 · Cited by 27
“vant candidate genes have not yet been accomplished 41 [1].”
Caberlotto, L., Marchetti, L., Lauria, M., Scotti, M., & Parolo, S. (2016) · Scientific Reports · doi:10.1038/srep32583 · Cited by 31
“3B) of APOE and the epistasis genes, as well as of APP and PSEN1, genes on which mutations are responsible for the familiar form of AD 34 , could give a mechanistic hypothesis on how these genetic alterations lead to the earlier onset of the disease.”
Han, Y., Chen, L., Guo, Y., Wang, C., Zhang, C., Kong, L., & Ma, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.619866 · Cited by 28
“Even though it is generally believed that the pathogenesis of AD is related to genetic factors, neurotransmitters, immune and environmental factors, et cetera (Bertram and Tanzi, 2008), the pathogenesis of AD is still unclear.”
BackgroundDual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Zhang, X., & Ran, C. (2013) · Current Organic Chemistry · doi:10.2174/1385272811317060004 · Cited by 27
Induced Pluripotent Stem Cells to Model and Treat Neurogenetic Disorders
Wang, H., & Doering, L. C. (2012) · Neural Plasticity · doi:10.1155/2012/346053 · Cited by 32
Resveratrol Derived Butyrylcholinesterase Inhibitors
Csük, R., Albert, S., Kluge, R., & Ströhl, D. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201300051 · Cited by 27
Vargas-Rodríguez, P., Cuenca-Martagón, A., Castillo-González, J., Serrano-Martínez, I., Luque, R. M., Delgado, M., & González-Rey, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814117 · Cited by 25
“While genetic factors may potentially contribute to its development, specific mutations that directly cause an increase in proteolytic cleavage in patients have not been observed [103].”
Imaging Approaches for Dementia
Murray, A. D. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2782 · Cited by 27
The Significance of Discovery Screening and Structure Optimization Studies
Osakwe, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802220-7.00005-3 · Cited by 40
Fletcher, T. L., & Popelier, P. L. A. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00457 · Cited by 25
Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage
Netzer, W. J., Bettayeb, K., Sinha, S. C., Flajolet, M., Greengard, P., & Bustos, V. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620963114 · Cited by 29
“R mutations in amyloid precursor protein (APP) occur in select families, where they are inherited as autosomal dominant genes that invariably cause early-onset Alzheimer’s disease (AD) and are referred to as familial AD (FAD) mutations (1, 2).”
BackgroundProtective Effects of the Caffeine Against Neurodegenerative Diseases
Tellone, E., Galtieri, A., Russo, A., & Ficarra, S. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171009104040 · Cited by 25
Lu, M., Ji, W., Xu, D.-E., Yao, P.-P., Zhao, X., Wang, Z., Fang, L., Huang, R., Lan, L.-J., Chen, J.-B., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.012 · Cited by 26
Malik, B. A., Fernandes, C., Killick, R., Wroe, R., Usardi, A., Williamson, R., Kellie, S., Anderton, B. H., & Reynolds, C. H. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.05.006 · Cited by 28
“, 2007); and CH25H, which converts cholesterol to 25hydroxycholesterol, a transcriptional regulator of steroid and lipid metabolic enzymes (reviewed in (Bertram and Tanzi, 2008).”
BackgroundWang, L., Tian, Y., Yu, J., Chen, W., Wu, Z., Zhang, Q., Zhang, W., & Tan, L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.12.008 · Cited by 26
Xuan, C., Zhang, B., Li, M., Deng, K., Yang, T., & Zhang, X. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.040 · Cited by 25
Xu, W. L., Xu, J. L., Wang, Y., Tang, H., Deng, Y., Ren, R., Wang, G., Niu, W., Ma, J., Wu, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063621 · Cited by 24
“APOE e4 allele may account for nearly 50% of the genetic risk in LOAD [8,9].”
BackgroundNo association between cytokine gene polymorphism and risk of Alzheimer´s disease in Slovaks
Shawkatová, I., Javor, J., Párnická, Z., Vrazda, L., Novák, M., & Buc, M. (2010) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2010-1802 · Cited by 27
Montufar-Armendariz, S., Calero, C., Vinueza‐Gavilanes, R., Correa, P., Carrera-Gonzalez, A., Villegas, F., Moreta, G., & Paredes, R. (2017) · International Journal of Alzheimer s Disease · doi:10.1155/2017/1059678 · Cited by 32
“This observation confirms that although the APOE ε4 allele is confirmed as a risk factor for AD, it is neither necessary nor sufficient to develop the disease, so there are probably other factors acting [42, 50, 51].”
BackgroundZhang, S., Bai, P., Lei, D., Liang, Y., Zhen, S. Y., Bakiasi, G., Pang, H., Choi, S. H., Wang, C., Tanzi, R. E., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101794 · Cited by 32
Self-citationWei, J., Qiu, Z., Yu, D., Yin, Y., Tang, Q., Liao, X., Zhang, G., Liu, Z., & Gao, F. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133656 · Cited by 24
Luo, J., Li, S., Qin, X. Y., Song, L., Peng, Q., Chen, S., Xie, Y., Xie, L., Li, T., He, Y., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.06.055 · Cited by 24
Emerging preclinical pharmacological targets for Parkinson's disease
More, S. V., & Choi, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8104 · Cited by 26
Park, M. H., Yun, H., Hwang, C. J., Park, S. I., Han, S., Hwang, D. Y., Yoon, D., Kim, S., & Hong, J. T. (2017) · Theranostics · doi:10.7150/thno.21408 · Cited by 22
“catalytic subunits of β- and γ-secretase [1, 2].”
Alterations of functional circuitry in aging brain and the impact of mutated APP expression
Bearer, E. L., Manifold-Wheeler, B. C., Medina, C. S., Gonzales, A., Chaves, F. L., & Jacobs, R. E. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.018 · Cited by 26
Identification and Analysis of Alzheimer’s Candidate Genes by an Amplitude Deviation Algorithm
Pang, C.-Y., Yang, H., Hu, B.-Q., Wang, S., Chen, M., Cohen, D. S., Chen, H. S., Jarrell, J. T., Carpenter, K. A., Rosin, E. R., et al. (2019) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000460 · Cited by 25
“It is of common opinion that AD is related to amyloid plaques (Aβ) and neurofibrillary tangles (NFT) in the brain [1,2].”
BackgroundPresenilins as endoplasmic reticulum calcium leak channels and Alzheimer’s disease pathogenesis
Supnet, C. B., & Борисович, Б. И. (2011) · Science China Life Sciences · doi:10.1007/s11427-011-4201-y · Cited by 25
Human stem cell models of dementia
Livesey, F. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu302 · Cited by 22
“These mutations account for ,1% of all AD and strongly implicate altered APP processing as the key initiating event in the disease (15).”
BackgroundAdvances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia
Eisenmenger, L. B., Huo, E. J., Hoffman, J. M., Minoshima, S., Matesan, M. C., Lewis, D. H., Lopresti, B. J., Mathis, C. A., Okonkwo, D. O., & Mountz, J. M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.09.003 · Cited by 26
“Mutations in three genes—amyloid precursor protein (APP), presenilin 1, and presenilin 2—cause an early-onset, autosomal, and dominantly inherited AD.(31) The major genetic risk factor for late-onset AD is the e4 allele of the APOE gene, which is involved in Aβ trafficking.”
BackgroundNeurosteroids and Oxysterols as Potential Therapeutic Agents for Glaucoma and Alzheimer’s Disease
Ishikawa, M., Yoshitomi, T., Covey, D. F., Zorumski, C. F., & Izumi, Y. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000356 · Cited by 23
He, P., Li, P., Hua, Q., Liu, Y., Staufenbiel, M., Li, R., & Shen, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058181 · Cited by 22
“To further confirm whether the decreased Ab deposition induced by herbal medicine TLJN administration in APP23 mouse brains was due to insoluble Ab reduction, we measured the levels of insoluble Ab40 and Ab42 by sandwich ELISAs (n= 10 each group) [34,36], which are primary Ab species existing in amyloid plaques in AD…”
BackgroundMethodWang, W., Yu, J., Tan, L., Liu, Q., Wang, H.-F., & Ma, X. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.10.015 · Cited by 23
Modulation of APOE and SORL1 genes on hippocampal functional connectivity in healthy young adults
Shen, J., Qin, W., Xu, Q., Xu, L., Xu, J., Zhang, P., Liu, H., Liu, B., Jiang, T., & Yu, C. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1377-3 · Cited by 23
“2011), but it is neither necessary nor sufficient for AD (Bertram and Tanzi 2008; Slooter et al. 1998).”
BackgroundInfluentialChapter 8 The Molecular and Cellular Pathogenesis of Dementia of the Alzheimer's Type
Luque, F. A., & Jaffe, S. L. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)00408-5 · Cited by 24
Kitzlerová, E., Fišar, Z., Lelková, P., Jirák, R., Zvěřová, M., Hroudová, J., Manukyan, A., Martásek, P., & Raboch, J. (2018) · Medical Science Monitor · doi:10.12659/msm.907202 · Cited by 21
Novel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease
Pham, A. Q., & Dore, K. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.032 · Cited by 21
Pandey, R. S., Arnold, M., Batra, R., Krumsiek, J., Kotredes, K. P., Garceau, D. T., Williams, H. M., Sasner, M., Howell, G. R., Kaddurah‐Daouk, R., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13851 · Cited by 22
Wang, Y., Wang, C., Cheng, Z., Zhang, D., Li, S., Song, L., Zhou, W., Yang, M., Wang, Z., Zheng, Z., et al. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.11.025 · Cited by 21
Fine mapping of the chromosome 10q11-q21 linkage region in Alzheimer's disease cases and controls
Fallin, M. D., Szymanski, M., Wang, R., Gherman, A., Bassett, S. S., & Avramopoulos, D. (2010) · Neurogenetics · doi:10.1007/s10048-010-0234-9 · Cited by 22
“The APOE gene, encoding apolipoprotein E, is the first and strongest established susceptibility gene for LOAD, while several other promising candidates have been associated in multiple studies and populations [1], and new ones are emerging from genome-wide association studies (GWAS) [2–13].”
BackgroundThe Physical Activity and Alzheimer’s Disease (PAAD) Study: Cognitive outcomes
Etnier, J. L., Karper, W. B., Labban, J. D., Piepmeier, A. T., Shih, C.-H., Dudley, W. N., Henrich, V. C., & Wideman, L. (2018) · Annals of Behavioral Medicine · doi:10.1093/abm/kax035 · Cited by 27
“There is a dose-response relationship between the APOE epsilon 4 (ɛ4) allele and the risk of AD, with one copy of the ɛ4 allele resulting in 3–4 times [20, 21] and 2 copies of the ɛ4 allele resulting in 5–18 times [22] greater risk as compared to persons without the ɛ4 allele (noncarriers).”
BackgroundZhang, C., Browne, A., Kim, D., & Tanzi, R. E. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274428 · Cited by 20
“Most mutations in APP, PSEN1, and PSEN2 increase the ratio of Aβ42:Aβ40, which accelerates the oligomerization of Aβ into neurotoxic assemblies [1, 2].”
BackgroundSelf-citationA Human-Based Integrated Framework forAlzheimer’s Disease Research
Pistollato, F., Cavanaugh, S. E., & Chandrasekera, P. C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150281 · Cited by 23
“Familial AD is generally characterized by the presence of mutations found in genes encoding the -secretase complex components, such as presenilin-1 and −2, or in the amyloid- (A4) protein precursor (A PP) [11].”
Neuroprotective Effects of Lipoxin A4 in Central Nervous System Pathologies
Martini, A. C., Forner, S., Bento, A. F., & Rae, G. A. (2014) · BioMed Research International · doi:10.1155/2014/316204 · Cited by 20
Enhanced dentate gyrus synaptic plasticity but reduced neurogenesis in a mouse model of amyloidosis
Poirier, R., Veltman, I., Pflimlin, M., Knoflach, F., & Metzger, F. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.06.014 · Cited by 22
“Mutations in genes coding for amyloid precursor protein (APP), presenilin (PS) 1 and PS2 have been linked to early-onset AD (Bertram and Tanzi, 2008), and overexpression in transgenic mice partially reproduced AD pathologies such as Aβ aggregation, decreased LTP, impaired neurogenesis and cognitive…”
BackgroundFowler, K. D., Funt, J. M., Artyomov, M. N., Zeskind, B. J., Kolitz, S. E., & Towfic, F. (2015) · Scientific Reports · doi:10.1038/srep14324 · Cited by 22
Chun, Y. S., Kim, J., Chung, S., Khorombi, E., Naidoo, D., Nthambeleni, R., Harding, N., Maharaj, V. J., Fouché, G., & Yang, H. O. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04451 · Cited by 22
Genomics: New Light on Alzheimer’s Disease Research
Jung, Y. J., Kim, Y. H., Bhalla, M., Lee, S. B., & Seo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123771 · Cited by 20
“, the so-called “amyloid cascade hypothesis”) [8,9].”
Versorgungs-Report Früherkennung
Günster, C., Klauber, J., Robra, B.-P., Schmacke, N., Schmuker, C., & KG, M. M. W. V. M. &. C. (2019) · Medizinisch Wissenschaftliche Verlagsgesellschaft eBooks · doi:10.32745/9783954664542 · Cited by 29
Prawiroharjo, P., Yamashita, K., Yamashita, K., Togao, O., Hiwatashi, A., Yamasaki, R., & Kira, J. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04516 · Cited by 22
“Additionally, we focused our analysis on the DMN because it is closely involved in AD pathology (Greicius et al., 2004; Mevel et al., 2011); the DMN is a key network that deteriorates in EOAD and especially in LOAD (Badhwar et al., 2017; Brier et al., 2014).”
BackgroundInfluentialWoodard, J. L., & Sugarman, M. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_159 · Cited by 23
“1993) and possession of one or more apolipoprotein E (APOE) e4 alleles (Bertram and Tanzi 2008; Corder et al. 1993; Saunders et al. 1993) are two well-known risk factors for AD.”
BackgroundA study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease
Laumet, G. O., Petitprez, V., Sillaire, A. R., Ayral, A., Hansmannel, F., Chapuis, J., Hannequin, D., Pasquier, F., Scarpini, E. A., Galimberti, D., et al. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.040 · Cited by 20
Huang, Y., Hu, Y., Jin, Z., & Shen, Z. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.152 · Cited by 21
Upregulation of neuronal ER-phagy improves organismal fitness and alleviates APP toxicity
Mou, W., Tang, Y., Huang, Y., Wu, Z., & Cui, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114255 · Cited by 20
BioN∅T: A searchable database of biomedical negated sentences
Agarwal, S., Yu, H. Q., & Kohane, I. S. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-420 · Cited by 19
“We consulted published reviews to identify genes thought to be associated with these diseases and found 26 putative genes for autism (see Table Two in [16]), 10 for Alzheimer’s disease (see Table Two in [17]), and 6 for Parkinson’s disease (see Table Two in [18]).”
MethodNew Insight into Neurodegeneration: the Role of Proteomics
Pal, R., Alves, G. W., Larsen, J. P., & Møller, S. G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8590-8 · Cited by 22
“Genes encoding Amyloid Precursor Protein (APP), Presenilin 1 (PS1), and Presenilin 2 (PS2) have been linked to early-onset familial forms of AD [12, 13].”
BackgroundZhang, L., Liao, J.-X., Liu, Y.-Y., Luo, H.-L., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1280186 · Cited by 22
Inekci, D., Jonesco, D. S., Kennard, S., Karsdal, M. A., & Henriksen, K. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00090 · Cited by 19
“TheApoE ε4 allele is a risk factor for late-onset familial and sporadic AD (18, 108).”
BackgroundSodium Chloride Increases Aβ Levels by Suppressing Aβ Clearance in Cultured Cells
Cheng, X., Gao, Y., Zhao, Y., & Cheng, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130432 · Cited by 21
“For sporadic AD which accounts for 90% of all AD cases, its underlining mechanism appears to be much more complex and only less than 50% of sporadic AD cases could be attributed to genetic factors [1].”
BackgroundStone, D. J., Molony, C. M., Suver, C., Schadt, E. E., & Potter, W. Z. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.58 · Cited by 19
Li, Y., Seidel, K., Marschall, P., Klein, M., Hope, A., Schacherl, J., Schmitz, J., Menk, M., Schefe, J. H., Reinemund, J., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2636-12.2012 · Cited by 20
“Nevertheless, genome-wide association studies (GWAS), which focus on SNPs, have only revealed loci with modest effects on AD risk (Bertram and Tanzi, 2008).”
BackgroundHigh apolipoprotein E4 allele frequency in FXTAS patients
Silva, F., Rodríguez‐Revenga, L., Madrigal, I., Álvarez‐Mora, M. I., Oliva, R., & Milà, M. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.12 · Cited by 20
de Oliveira, F. F., Berretta, J. M., Chen, E., Smith, M. D. A. C., & Bertolucci, P. H. F. (2016) · Colombia medica · doi:10.25100/cm.v47i2.2188 · Cited by 19
Wang, X., Philip, V. M., Ananda, G., White, C. C., Malhotra, A., Michalski, P. J., Karuturi, K., Chintalapudi, S. R., Acklin, C. J., Sasner, M., et al. (2018) · Genetics · doi:10.1534/genetics.117.300673 · Cited by 22
“Variations in apolipoprotein E (APOE) are the greatest genetic risk factor, with the e4 allele conferring a 30–50% increased risk for AD (Bertram and Tanzi 2008).”
BackgroundCHIP modulates APP‐induced autophagy‐dependent pathological symptoms in Drosophila
Zhuang, L., Peng, F., Huang, Y., Li, W., Huang, J., Chu, Y., Ren, P., Sun, Y., Zhang, Y., Xue, E., et al. (2019) · Aging Cell · doi:10.1111/acel.13070 · Cited by 21
“Genetic studies of familial AD (FAD) have identified mutations in APP and its associated genes in the early‐onset AD (Bertram & Tanzi, 2008), This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,…”
Background
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, Lars
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 768-778
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2018342879
- Cited by
- 747
- References
- 113
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 26 · 2020: 29 · 2019: 34 · 2018: 41 · 2017: 46 · 2016: 37 · 2015: 41 · 2014: 46 · 2013: 59 · 2012: 62
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (5R01-AG23667, R01AG023667)
- National Institute of Mental Health (5R37MH60009, R37MH060009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease genetics, genetic risk factors, candidate genes, meta-analysis, amyloid precursor protein, presenilin 1, presenilin 2, apolipoprotein E, early-onset familial Alzheimer's disease, late-onset Alzheimer's disease, disease pathology, metabolic pathways
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain Chemistry, Humans, Mutation, Risk Factors, Meta-Analysis as Topic, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.